Search

Your search keyword '"Fergusson, W."' showing total 251 results
Start Over Author "Fergusson, W."
251 results on '"Fergusson, W."'

2. Taurine transporter in fetal T lymphocytes and platelets: differential expression and functional activity

Author

Iruloh, C.G., D'Souza, S.W., Speake, P.F., Crocker, I., Fergusson, W., Baker, P.N., Sibley, C.P., and Glazier, J.D.

Subjects
Taurine -- Research, Messenger RNA -- Physiological aspects, Messenger RNA -- Research, Fetus -- Growth retardation, Fetus -- Research, Biological sciences
Abstract

Transplacental transfer of taurine, a [beta]-amino acid essential for fetal and neonatal development, constitutes the primary source of taurine for the fetus. Placental transport of taurine is compromised in pregnancies complicated by intrauterine growth restriction, resulting in a reduced concentration of taurine in cord plasma. This could impact on fetal cellular metabolism as taurine represents the most abundant intracellular amino acid in many fetal cell types. In the present study, we have used pure isolates of fetal platelets and T lymphocytes from cord blood of placentas, from normal, term pregnancies, as fetal cell types to examine the cellular uptake mechanisms for taurine by the system [beta] transporter and have compared gene and protein expression for the taurine transporter protein (TAUT) in these two cell types. System [beta] activity in fetal platelets was 15-fold higher compared with fetal T lymphocytes (P < 0.005), mirroring greater TAUT mRNA expression in platelets than T lymphocytes (P < 0.005). Cell-specific differences in TAUT protein moieties were detected with a doublet of 75 and 80 kDa in fetal platelets compared with 114 and 120 kDa in fetal T lymphocytes, with relatively higher expression in platelets. We conclude that greater system [beta] activity in fetal platelets compared with T lymphocytes is the result of relatively greater TAUT mRNA and protein expression. This study represents the first characterization of amino acid transporters in fetal T lymphocytes. cord blood cells; amino acid; taurine transporter protein; system [beta]

Published
2007

19. Reports Of Societies

Author

Fergusson, W., Habershon, S. O., Harley, John, and Desmond, L. E.

Published
1864

32. Reports Of Societies

Author

Fergusson, W., Sweeting, William, Locock, C., Erichsen, John E., Cattlin, W. A. N., Roe, G. Hamilton, Heslop, T., and Cooke, Weeden

Published
1858

41. Azithromycin for prevention of exacerbations in non-cystic fi brosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial.

Author

Storey L., Ashton T., Wong C., Jayaram L., Karalus N., Eaton T., Tong C., Hockey H., Milne D., Fergusson W., Tuffery C., Sexton P., Storey L., Ashton T., Wong C., Jayaram L., Karalus N., Eaton T., Tong C., Hockey H., Milne D., Fergusson W., Tuffery C., and Sexton P.

Abstract

Background Azithromycin is a macrolide antibiotic with anti-infl ammatory and immunomodulatory properties. We tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and improve health-related quality of life in patients with non-cystic fi brosis bronchiectasis. Methods We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis defi ned by highresolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratifi ed by centre. Participants, research assistants, and investigators were masked to treatment allocation. The coprimary endpoints were rate of eventbased exacerbations in the 6-month treatment period, change in forced expiratory volume in 1 s (FEV1) before bronchodilation, and change in total score on St George's respiratory questionnaire (SGRQ). Analyses were by intention to treat. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12607000641493. Findings 71 patients were in the azithromycin group and 70 in the placebo group. The rate of event-based exacerbations was 059 per patient in the azithromycin group and 157 per patient in the placebo group in the 6-month treatment period (rate ratio 038, 95% CI 026-054; p<00001). Prebronchodilator FEV1 did not change from baseline in the azithromycin group and decreased by 004 L in the placebo group, but the diff erence was not signifi cant (004 L, 95% CI -003 to 012; p=0251). Additionally, change in SGRQ total score did not diff er between the azithromycin (-517 units) and placebo groups (-192 units; diff erence -325, 95% CI

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results